BGNE BeiGene Ltd.

186.92
-2.28  -1%
Previous Close 189.2
Open 190
Price To Book 8.93
Market Cap 11,415,621,045
Shares 61,072,229
Volume 508,025
Short Ratio
Av. Daily Volume 369,622
Stock charts supplied by TradingView

NewsSee all news

  1. BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  2. BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 23, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  3. U.S. FDA Grants BeiGene's BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

    - This marks the first FDA approval for BeiGene - 84% of patients taking BRUKINSA achieved an overall response1 - BRUKINSA is the only FDA-approved BTK inhibitor shown to deliver 100% median occupancy in peripheral

  4. BeiGene Reports Third Quarter 2019 Financial Results

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  5. BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 enrolment completed.
Tislelizumab
Hepatocellular carcinoma (HCC)
Phase 2 enrolment has been completed. Data due 2020.
Pamiparib (BGB-290)
Ovarian Cancers or Triple-Negative Breast Cancer
Phase 3 presentation at ASH Sunday, December 8, 2019 at 4:30pm ET.
Zanubrutinib (BGB-3111) - SEQUOIA
First-line chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Phase 1b data presented at ICML June 20, 2019 noted ORR 72-100%. Phase 2 trial is ongoing.
Zanubrutinib and Obinutuzumab
Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Phase 3 trial to be initiated 1H 2018.
Pamiparib (BGB-290)
Solid tumors - cancer
Phase 2 pivotial China trial initiation announced July 5, 2017.
BGB-A317
Urothelial cancer (UC) - bladder cancer
Phase 2 pivotal updated data presented at EHA June 2019 noted 87% ORR (63% CR).
Tislelizumab - BGB-A317
Relapsed or refractory classical Hodgkin lymphoma (cHL)
FDA Approval announced November 14, 2019.
Zanubrutinib (BGB-3111)
Relapsed or refractory mantle cell lymphoma (MCL)
Phase 3 top-line data due 4Q 2019.
Zanubrutinib (BGB-3111) - ASPEN
Waldenström’s macroglobulinemia
Phase 3 enrolment to be completed 1H 2020.
Tislelizumab - BGB-A317
Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2 data due 2019 or early 2020.
Tislelizumab
Hepatocellular carcinoma (HCC) - second-line
Phase 3 trial initiation announced July 24, 2018.
Pamiparib (BGB-290)
Gastric Cancer
Phase 3 data due 2020.
Pamiparib (BGB-290)
Maintenance Therapy Ovarian Cancer
Phase 3 enrolment to be completed in 2019 or early 2020.
Tislelizumab
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Tislelizumab
Squamous non-small cell lung cancer (NSCLC)
Phase 1/2 data presented at SNO November 16, 2018 noted 2/15 partial responses.
Pamiparib (BGB-290)
Glioblastoma (GBM)
Phase 3 data due 2H 2019.
Zanubrutinib (BGB-3111) vs Ibrutinib
Refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Phase 1b initial data due 4Q 2019.
Sitravatinib and tislelizumab
Solid tumors
Phase 3 commencement of enrolment announced December 17, 2018.
Tislelizumab
Gastric Cancer
Phase 1 updated data at EHA June 2019 noted 92% ORR.
Zanubrutinib (BGB-3111)
Waldenström’s macroglobulinemia
Phase 2 trial initiation announced February 19, 2019.
Zanubrutinib (BGB-3111) - MAGNOLIA
Marginal Zone Lymphoma
Phase 3 trial ongoing.
Tislelizumab
Nasopharyngeal cancer
Phase 3 trial ongoing.
Zanubrutinib plus rituximab
Mantle cell lymphoma (MCL) - front-line

Latest News

  1. BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  2. BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 23, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  3. U.S. FDA Grants BeiGene's BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

    - This marks the first FDA approval for BeiGene - 84% of patients taking BRUKINSA achieved an overall response1 - BRUKINSA is the only FDA-approved BTK inhibitor shown to deliver 100% median occupancy in peripheral

  4. BeiGene Reports Third Quarter 2019 Financial Results

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  5. BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  6. Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate

    -BeiGene and Seattle Genetics to Collaborate on Global Clinical Trials- Seattle Genetics, Inc. (NASDAQ:SGEN) and BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)) today announced that the companies have entered into a license

  7. BeiGene Announces Global Strategic Oncology Collaboration with Amgen

    • Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China  • Companies to Jointly Develop 20 Amgen Oncology Pipeline Assets, with BeiGene

  8. Bragar Eagel & Squire, P.C. Is Investigating Tandy Leather Factory, ADTRAN, BeiGene, and Altria Group on Behalf of Stockholders and Encourages Investors to Contact the Firm

    NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Tandy Leather Factory, Inc. (NASDAQ:TLF), ADTRAN, Inc. (NASDAQ:ADTN), BeiGene, Ltd. (NASDAQ:BGNE),

  9. BGNE INVESTOR REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud

    SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds BGNE investors that it has launched an investigation into BeiGene, Ltd. (NASDAQ:BGNE) regarding possible violations of Federal securities laws,

  10. BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019

    CAMBRIDGE, Mass. and BEIJING, China, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  11. BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019

    CAMBRIDGE, Mass. and BEIJING, China, Sept. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  12. BGNE INVESTIGATION REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud

    SAN FRANCISCO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds BGNE investors that it has launched an investigation into BeiGene, Ltd. (NASDAQ:BGNE) regarding possible violations of Federal securities laws,

  13. BeiGene Announces Clinical Results on Tislelizumab Presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

    BEIJING, China and CAMBRIDGE, Mass., Sept. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  14. BGNE SHAREHOLDER ALERT: Hagens Berman Reminds Investors in BeiGene, Ltd. (BGNE) of Ongoing Investigation of Possible Securities Fraud

    SAN FRANCISCO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds BGNE investors that it has launched an investigation into BeiGene, Ltd. (NASDAQ:BGNE) regarding possible violations of Federal securities laws,

  15. Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of BeiGene, Ltd. Investors

    Glancy Prongay & Murray LLP ("GPM")

  16. INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation on Behalf of BeiGene, Ltd. Investors (BGNE)

    Law Offices of Howard G. Smith continues its investigation on behalf of BeiGene, Ltd. ("BeiGene" or the "Company") (NASDAQ: BGNE) investors concerning the Company and its officers' possible violations of federal securities laws.

  17. Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. (NASDAQ: BGNE) on Behalf of BeiGene Stockholders and Encourages BeiGene Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. is investigating potential claims against BeiGene, Ltd. (NASDAQ:BGNE) on behalf of BeiGene stockholders. Our investigation concerns whether BeiGene has violated the federal securities

  18. Glancy Prongay & Murray LLP Announces Investigation on Behalf of BeiGene, Ltd. Investors

    Glancy Prongay & Murray LLP ("GPM")

  19. SHAREHOLDER ALERT: Hagens Berman Notifies Investors in BeiGene, Ltd. (BGNE) of Securities Fraud Investigation

    SAN FRANCISCO, Sept. 12, 2019 /PRNewswire/ -- Hagens Berman has launched an investigation into BeiGene, Ltd. (NASDAQ:BGNE) regarding possible violations of Federal securities laws, and is urging investors to find out

  20. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of BeiGene, Ltd. Investors (BGNE)

    Law Offices of Howard G. Smith announces an investigation on behalf of BeiGene, Ltd. ("BeiGene" or the "Company") (NASDAQ: BGNE) investors concerning the Company and its officers' possible violations of federal securities laws.

  21. BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

    BEIJING, China and CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  22. BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update

    CAMBRIDGE, Mass. and BEIJING, China, Sept. 08, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  23. BeiGene to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    CAMBRIDGE, Mass. and BEIJING, China, Sept. 03, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative